Introduction
Freenome is a South San Francisco biotechnology company founded in 2014 that develops blood-based cancer screening tests using an artificial intelligence-enabled multiomics platform. Aaron Elliott, Ph.D., serves as chief executive officer — a role Freenome confirmed in an April 8, 2025 newsroom announcement and on its dedicated CEO page reviewed in July 2026. Riley Ennis, co-founder, serves as chief product officer and remains a public voice for Freenome’s clinical and commercial development strategy.
Freenome’s tests target early detection in colorectal, lung, and additional cancer types, with commercialization partnerships and a announced business combination intended to support public-market scaling.
What the company does
Freenome combines genomic, proteomic, and methylation signals with machine learning to detect cancer and precancerous conditions from blood draws suitable for primary care settings. Its colorectal cancer program includes SimpleScreen CRC, which Freenome has positioned following pivotal PREEMPT CRC study results and journal publication. The company also advances lung cancer screening and broader multi-cancer detection pipelines, emphasizing personalized, accessible screening integrated into routine care rather than specialty oncology workflows alone.
Freenome’s multiomics approach trains models on combined molecular feature sets rather than single-analyte assays — a design choice Elliott has emphasized when describing commercial readiness under his CEO tenure. Laboratory operations run from Freenome’s South San Francisco base with CLIA-certified workflows intended to support health-system and partner distribution once regulatory milestones clear.
Who it serves
Freenome serves health systems, primary care networks, payers, and employers seeking alternatives or complements to stool-based or imaging screening modalities. An exclusive license agreement with Exact Sciences to commercialize Freenome’s CRC blood test — referenced in Freenome newsroom materials — expands distribution reach if regulatory approvals proceed. Pharmaceutical and diagnostic partners also access Freenome’s platform for biomarker and trial applications.
Primary care physicians remain the intended ordering channel for population screening — Freenome’s workflow design assumes blood draws fit routine visits better than colonoscopy scheduling for average-risk adults who defer preventive care.
Company background
Riley Ennis co-founded Freenome in 2014, bringing early biotech entrepreneurship experience to the company’s mission of making cancer screening accessible. Aaron Elliott joined as CEO in April 2025 from diagnostics leadership roles including REALM IDx and Ambry Genetics, where he led multiomic test commercialization. Freenome announced a business combination agreement with Perceptive Capital Solutions Corp in December 2025, framing a path toward public listing to fund multi-test launches expected in 2026, subject to shareholder and regulatory approvals stated in the release.
Freenome’s South San Francisco base situates it among other multiomics diagnostics companies targeting blood-based screening, a geography with dense talent pools in computational biology and CLIA laboratory operations.
Product and AI capabilities
Freenome’s platform applies AI and deep learning across multiomic feature sets trained on large clinical datasets, including real-world training data Freenome highlights in NVIDIA-accelerated initiatives announced in its newsroom. The company emphasizes diagnostic yield and performance in average-risk populations — a design choice reflected in PREEMPT CRC enrollment and subsequent JAMA publication cited by Elliott in official statements. AI here supports pattern recognition across molecular modalities humans cannot manually score at scale, but Freenome’s regulatory path remains tied to clinical validation outcomes, not model architecture alone.
Key developments
2014: Freenome founded; Riley Ennis co-founder. April 8, 2025: Aaron Elliott, Ph.D., appointed CEO (Freenome newsroom). December 5, 2025: Business combination agreement with Perceptive Capital Solutions Corp announced (Freenome newsroom). Brel does not describe the transaction as completed unless Freenome primary releases confirm close.
Elliott’s April 2025 appointment preceded major 2025–2026 newsroom milestones including Exact Sciences licensing and PREEMPT CRC publication references in Freenome official communications — a timeline consistent with commercialization acceleration under new operating leadership.
Why it matters
Freenome matters because blood-based CRC screening could materially expand adherence if primary care adoption proves viable — a market with multiple well-funded entrants but few scaled winners. Elliott’s CEO appointment signals a commercialization-focused chapter after years of clinical validation. Exact Sciences partnership and the pending public listing, if completed, would test whether multiomics AI screening can reach employer and health-system channels faster as a partnered product than as a standalone startup brand.
Payers and employers should track FDA decision timelines and guideline inclusion separately from partnership press releases — commercial agreements do not substitute for coverage policy. Freenome’s emphasis on average-risk PREEMPT CRC enrollment addresses a screening population underserved by colonoscopy adherence alone.
Sector context
Freenome belongs in Brel’s AI in healthcare coverage under biotechnology and multiomics diagnostics, distinct from imaging screening companies such as Ezra or digital pathology vendors. Readers should track regulatory clearance status and commercial partner announcements separately — partnership agreements are not equivalent to FDA approval or national coverage decisions.
Blood-based screening AI competes on longitudinal adherence and primary-care ordering friction — technical sensitivity alone does not win market share if patients never complete the draw or physicians never see results in workflow.
Sources and references
Freenome CEO appointment newsroom release (April 8, 2025) and CEO profile page.
- Freenome — Aaron Elliott appointed CEO (freenome.com, April 8, 2025)
- Freenome — Chief Executive Officer page (freenome.com)
Reviewed July 10, 2026. Aaron Elliott is CEO; Riley Ennis is co-founder and CPO.